AMsilk scaling up through Evonik collaboration
Fermatation expert Evonik SE has entered into an agreement with the German recombinant silk producer AMSilk to produce industrial quantities of innovative, sustainable silk proteins.
HOOKIPA bags US$10m cancer milestone
HOOKIPA has received a US$10m milestone under its 2022 agreement with Roche to develop an arenaviral immunotherapy for KRAS-mutated cancers.
Cydar Medical Ltd raises 10.5m in Series A financing
Cambridge-based endovascular surgical AI specialist Cydar Medical has completed a 10.5m (£9.3m) Series A funding round led by Pembroke Venture Capital Trust
Evonetix extends Series B financing to US$54m
British Evonetix Ltd has added US$$24m to its existing US$30m Series B financing round. The new financing was led by existing investor Foresite Capital.
Germanys Curevac offers common shares
mRNA vaccine pioneer CureVac N.V. has announced that it will sell US$200m of its common shares in an underwritten public offering.
Chong Kun Dang Pharm licences Synaffix ADC platform
South Korean Chong Kun Dang Pharm has licenced access to Amsterdam-based Synaffix BVs propietary ADC platform.
New EU stakeholder platform to speed up clinical trials
A new platform is set to facilitate the exchange of information on the optimisation of the electronic reporting system CTIS.
Ultra-processed foods increase risk for cancer
British researchers have linked higher consumption of ultra-processed foods to an increased risk of developing and dying from cancer.
Evotec and Janssen team up in immunooncology
Evotec SE and Janssen Biotech Inc have agreed to co-develop targeted immuno-oncological therapies.
Evidence of deliberate climate damage
A new study adds weight to ongoing legal and political investigations against ExxonMobil for deliberate climate malfeasance.